Page last updated: 2024-11-04

ag-1549

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

capravirine: a non-nucleoside reverse transcriptase inhibitor [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID1783
CHEMBL ID435128
SCHEMBL ID40347
MeSH IDM0492371

Synonyms (43)

Synonym
D03371
capravirine (usan/inn)
5-(3,5-dichlorophenyl)thio-4-isopropyl-1-(pyridin-4-yl-methyl)-1h-imidazol-2-yl-methyl carbamate
S11 ,
5-(3,5-dichlorophenyl)thio-4-isopropyl-1-(4-pyridyl)methyl-1h-imidazol-2-ylmethyl carbamate
ag1549
capravirine
ag-1549
[5-(3,5-dichlorophenyl)sulfanyl-4-isopropyl-1-(4-pyridylmethyl)imidazol-2-yl]methyl carbamate
178979-85-6
s-1153 ,
cdimi
5-((3,5-dichlorophenyl)thio)-4-isopropyl-1-(4-pyridylmethyl)imidazole-2-methanol carbamate (ester)
ag 1549
s 1153
1h-imidazole-2-methanol, 5-((3,5-dichlorophenyl)thio)-4-(1-methylethyl)-1-(4-pyridinylmethyl)-, carbamate (ester)
bdbm27579
{5-[(3,5-dichlorophenyl)sulfanyl]-4-(propan-2-yl)-1-(pyridin-4-ylmethyl)-1h-imidazol-2-yl}methyl carbamate
DB08502
CHEMBL435128
[5-(3,5-dichlorophenyl)sulfanyl-4-propan-2-yl-1-(pyridin-4-ylmethyl)imidazol-2-yl]methyl carbamate
vhc779598x ,
ag 549
capravirine [usan:inn]
unii-vhc779598x
capravirine [mi]
5-[(3,5-dichlorophenyl)thio]-4-isopropyl-1-(4-pyridylmethyl)imidazole-2-methanol carbamate (ester)
capravirine [inn]
capravirine [who-dd]
capravirine [usan]
SCHEMBL40347
YQXCVAGCMNFUMQ-UHFFFAOYSA-N
2-carbamoyloxymethyl-5-(3,5-dichlorophenylthio)-4-isopropyl-1-(pyridin-4-yl)methyl-1h-imidazole
5-(3,5-dichlorophenylthio)-4-isopropyl-1-(4-pyridylmethyl)-1h-imidazol-2-ylmethyl carbamate
DTXSID30170689
{5-[(3,5-dichlorophenyl)sulfanyl]-4-(1-methylethyl)-1-(pyridin-4-ylmethyl)-1h-imidazol-2-yl}methyl carbamate
Q5036216
agi 549; capravirine; s 1153
(5-((3,5-dichlorophenyl)thio)-4-isopropyl-1-(pyridin-4-ylmethyl)-1h-imidazol-2-yl)methyl carbamate
5-(3,5-dichlorophenyl)thio-4-isopropyl-1-(pyridin-4-yl)methyl-1h-imidazol-2-ylmethyl carbamate
EX-A6254
Z2574923381
AKOS040748084

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" Capravirine was well absorbed in rats but only moderately so in dogs."( Evaluation of capravirine as a CYP3A probe substrate: in vitro and in vivo metabolism of capravirine in rats and dogs.
Bu, HZ; Kang, P; Pool, WF; Shetty, BV; Wu, EY; Zhao, P, 2007
)
0.34

Dosage Studied

ExcerptRelevanceReference
" The pharmacokinetic profile of GS-9160 in healthy human volunteers revealed that once-daily dosing was not likely to achieve antiviral efficacy; hence, the clinical development of this compound was discontinued."( Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
Chen, J; Chen, X; Geleziunas, R; Hesselgesser, J; Jin, H; Jones, GS; Kim, CU; Tsiang, M; Wright, M; Yu, F; Zeynalzadegan, A, 2009
)
0.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Gag-Pol polyproteinHIV-1 M:B_HXB2RIC50 (µMol)0.05870.00060.91418.3200AID1798815
Reverse transcriptase/RNaseH Human immunodeficiency virus 1IC50 (µMol)0.05870.00011.076810.0000AID347085; AID347086; AID347087
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (2)

Processvia Protein(s)Taxonomy
viral life cycleGag-Pol polyproteinHIV-1 M:B_HXB2R
establishment of integrated proviral latencyGag-Pol polyproteinHIV-1 M:B_HXB2R
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Processvia Protein(s)Taxonomy
peptidase activityGag-Pol polyproteinHIV-1 M:B_HXB2R
integrase activityGag-Pol polyproteinHIV-1 M:B_HXB2R
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (42)

Assay IDTitleYearJournalArticle
AID541174Selectivity ratio of EC50 for antiviral activity against HIV1 harboring E92V, G140S and V151A mutation in catalytic core domain of integrase to EC50 for antiviral activity against wild-type HIV1 3B2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID446238Antiviral activity against HIV RF infected in human SupT1 cells2009Bioorganic & medicinal chemistry letters, Oct-15, Volume: 19, Issue:20
Pyrazole NNRTIs 4: selection of UK-453,061 (lersivirine) as a development candidate.
AID441301Metabolic stability in human liver microsomes assessed as half life2009Bioorganic & medicinal chemistry letters, Oct-01, Volume: 19, Issue:19
Pyrazole NNRTIs 1: design and initial optimisation of a novel template.
AID347088Antiviral activity against HIV1 NL4-3 in HeLaP4 reporter cell assessed as virus replication by FluorAceTM beta-galactosidase reporter assay2009Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4
Novel indazole non-nucleoside reverse transcriptase inhibitors using molecular hybridization based on crystallographic overlays.
AID541163Selectivity ratio of EC50 for antiviral activity against HIV1 harboring E92Q mutation in catalytic core domain of integrase to EC50 for antiviral activity against wild-type HIV1 3B2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID541165Selectivity ratio of EC50 for antiviral activity against HIV1 harboring E138K mutation in catalytic core domain of integrase to EC50 for antiviral activity against wild-type HIV1 3B2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID541175Selectivity ratio of EC50 for antiviral activity against HIV1 harboring G140S and Q148H mutation in catalytic core domain of integrase to EC50 for antiviral activity against wild-type HIV1 3B2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID541171Selectivity ratio of EC50 for antiviral activity against HIV1 harboring L74M and E92V mutation in catalytic core domain of integrase to EC50 for antiviral activity against wild-type HIV1 3B2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID541135Selectivity ratio of EC50 for antiviral activity against PI-resistant HIV1 harboring RTG48V, V82A and L90M mutant gene to EC50 for antiviral activity against wild-type HIV1 3B2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID541173Selectivity ratio of EC50 for antiviral activity against HIV1 harboring E138K and Q148K mutation in catalytic core domain of integrase to EC50 for antiviral activity against wild-type HIV1 3B2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID347086Inhibition of RNA-dependent DNA polymerase activity of HIV1 reverse transcriptase K103N mutant2009Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4
Novel indazole non-nucleoside reverse transcriptase inhibitors using molecular hybridization based on crystallographic overlays.
AID446236Inhibition of HIV reverse transcriptase2009Bioorganic & medicinal chemistry letters, Oct-15, Volume: 19, Issue:20
Pyrazole NNRTIs 4: selection of UK-453,061 (lersivirine) as a development candidate.
AID541109Antiviral activity against HIV1 3B infected in human MT-2 cells by two fold dilution method in presence of 10% FBS2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID541167Selectivity ratio of EC50 for antiviral activity against HIV1 harboring Q148K mutation in catalytic core domain of integrase to EC50 for antiviral activity against wild-type HIV1 3B2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID541166Selectivity ratio of EC50 for antiviral activity against HIV1 harboring G140S mutation in catalytic core domain of integrase to EC50 for antiviral activity against wild-type HIV1 3B2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID541133Selectivity ratio of EC50 for antiviral activity against NNRTI-resistant HIV1 harboring RTY181C mutant gene to EC50 for antiviral activity against wild-type HIV1 3B2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID541168Selectivity ratio of EC50 for antiviral activity against HIV1 harboring V151A mutation in catalytic core domain of integrase to EC50 for antiviral activity against wild-type HIV1 3B2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID347089Metabolic stability in human liver microsomes assessed as half life2009Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4
Novel indazole non-nucleoside reverse transcriptase inhibitors using molecular hybridization based on crystallographic overlays.
AID541162Selectivity ratio of EC50 for antiviral activity against HIV1 harboring L74M mutation in catalytic core domain of integrase to EC50 for antiviral activity against wild-type HIV1 3B2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID541129Selectivity ratio of EC50 for antiviral activity against NRTI-resistant HIV1 harboring RTK65R mutant gene to EC50 for antiviral activity against wild-type HIV1 3B2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID441306Lipophilicity log D of the compound2009Bioorganic & medicinal chemistry letters, Oct-01, Volume: 19, Issue:19
Pyrazole NNRTIs 1: design and initial optimisation of a novel template.
AID541169Selectivity ratio of EC50 for antiviral activity against HIV1 harboring N155H mutation in catalytic core domain of integrase to EC50 for antiviral activity against wild-type HIV1 3B2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID541130Selectivity ratio of EC50 for antiviral activity against NRTI-resistant HIV1 harboring RTM184V mutant gene to EC50 for antiviral activity against wild-type HIV1 3B2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID347087Inhibition of RNA-dependent DNA polymerase activity of HIV1 reverse transcriptase Y181C mutant2009Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4
Novel indazole non-nucleoside reverse transcriptase inhibitors using molecular hybridization based on crystallographic overlays.
AID347090Metabolic stability in human hepatocytes assessed as half life2009Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4
Novel indazole non-nucleoside reverse transcriptase inhibitors using molecular hybridization based on crystallographic overlays.
AID441303Inhibition of wild type HIV reverse transcriptase in presence of poly(rA) 300 template, (dT) 16 primer2009Bioorganic & medicinal chemistry letters, Oct-01, Volume: 19, Issue:19
Pyrazole NNRTIs 1: design and initial optimisation of a novel template.
AID541134Selectivity ratio of EC50 for antiviral activity against PI-resistant HIV1 harboring RTI84V, L90M mutant gene to EC50 for antiviral activity against wild-type HIV1 3B2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID525726Half life in human liver microsomes2010Journal of medicinal chemistry, Nov-25, Volume: 53, Issue:22
Nitrile-containing pharmaceuticals: efficacious roles of the nitrile pharmacophore.
AID446239Cytotoxicity against human SupT1 cells2009Bioorganic & medicinal chemistry letters, Oct-15, Volume: 19, Issue:20
Pyrazole NNRTIs 4: selection of UK-453,061 (lersivirine) as a development candidate.
AID541170Selectivity ratio of EC50 for antiviral activity against HIV1 harboring N155S mutation in catalytic core domain of integrase to EC50 for antiviral activity against wild-type HIV1 3B2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID541132Selectivity ratio of EC50 for antiviral activity against NNRTI-resistant HIV1 harboring RTK103N mutant gene to EC50 for antiviral activity against wild-type HIV1 3B2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID248354Concentration required to inhibit 50% viral production of human immunodeficiency virus type 1 (HIV-1-IIIB)2005Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7
Hierarchical database screenings for HIV-1 reverse transcriptase using a pharmacophore model, rigid docking, solvation docking, and MM-PB/SA.
AID541164Selectivity ratio of EC50 for antiviral activity against HIV1 harboring E92V mutation in catalytic core domain of integrase to EC50 for antiviral activity against wild-type HIV1 3B2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID525725Inhibition of HIV RT2010Journal of medicinal chemistry, Nov-25, Volume: 53, Issue:22
Nitrile-containing pharmaceuticals: efficacious roles of the nitrile pharmacophore.
AID541172Selectivity ratio of EC50 for antiviral activity against HIV1 harboring E92V and V151A mutation in catalytic core domain of integrase to EC50 for antiviral activity against wild-type HIV1 3B2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID446240Metabolic stability in human liver microsomes assessed as half life2009Bioorganic & medicinal chemistry letters, Oct-15, Volume: 19, Issue:20
Pyrazole NNRTIs 4: selection of UK-453,061 (lersivirine) as a development candidate.
AID541161Selectivity ratio of EC50 for antiviral activity against HIV1 harboring T66I mutation in catalytic core domain of integrase to EC50 for antiviral activity against wild-type HIV1 3B2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID347085Inhibition of RNA-dependent DNA polymerase activity of wild type HIV1 reverse transcriptase2009Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4
Novel indazole non-nucleoside reverse transcriptase inhibitors using molecular hybridization based on crystallographic overlays.
AID441302Inhibition of wild type HIV reverse transcriptase in presence of poly(rA) template, (dT) 12-18 primer2009Bioorganic & medicinal chemistry letters, Oct-01, Volume: 19, Issue:19
Pyrazole NNRTIs 1: design and initial optimisation of a novel template.
AID541131Selectivity ratio of EC50 for antiviral activity against NRTI-resistant HIV1 harboring RT-6TAMs mutant gene to EC50 for antiviral activity against wild-type HIV1 3B2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID441317Dissociation constant, pKa of the compound2009Bioorganic & medicinal chemistry letters, Oct-01, Volume: 19, Issue:19
Pyrazole NNRTIs 1: design and initial optimisation of a novel template.
AID1798815Reverse Transcriptase Assay from Article 10.1021/jm801322h: \\Novel Indazole Non-Nucleoside Reverse Transcriptase Inhibitors Using Molecular Hybridization Based on Crystallographic Overlays (dagger).\\2009Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4
Novel indazole non-nucleoside reverse transcriptase inhibitors using molecular hybridization based on crystallographic overlays.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (30)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's3 (10.00)18.2507
2000's25 (83.33)29.6817
2010's2 (6.67)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (9.68%)5.53%
Reviews5 (16.13%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other23 (74.19%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]